RE:RE:RE:RE:RE:Immunogen IncThis is the reality
"Nov 2023, Within the GOBLET study's latest data on pelareorep in combination with the PD-L1 inhibitor atezolizumab (atezo) and chemotherapy is new data, including a 6-month progression-free survival (PFS) rate was 72.9%, and a 6-month overall survival (OS) rate of 82.1%—both significantly high for the industry standard.
A 72.9% PFS at 6 months is a positive signal, as many other therapies struggle to reach such a high percentage of patients experiencing no progression at that point. The same goes for a 6-month OS of 82.1%, as it indicates that a significant majority of patients are surviving to this point, which is better than what is commonly seen. For reference, considering all stages of pancreatic cancer, only around 25 in every 100 (25%) survive their diagnosis for 1 year or more.